DCTN6

Across TCGA pan-cancer cohorts, DCTN6 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DCTN6 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher DCTN6 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DCTN6 expression acts as an unfavorable survival marker.

BRCA, BLCA, and SCLC are the cancer types where DCTN6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	DFS	Median	All	0.315	0.903	<.001	24	view →
BLCA	DFS	Median	All	0.155	0.625	.014	24	view →
SCLC	OS	Median	All	0.055	0.708	<.001	12	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

DCTN6–BRCA (DFS)

Open the BRCA breakdown →